A prospective randomized controlled trial for comparing neoadjuvant and adjuvant chemotherapy of thoracic esophageal cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036018

Enrollment

Unknown

Registered

2020-08-21

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

neoadjuvant group:chemotherapy before surgery

adjuvant group:chemotherapy after surgery

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with histologically proven esophageal cancer; 2. aged 18-75 years old. Patients with cTNM II/III thoracic operable esophageal lesion. Staging investigations including esophagogastroscopy, chest and abdominal CT scan, barium swallow and selective endoscopic ultrasonography. 3. Karnofsky performance status greater than or equal to 80%; 4. Pulmonary and cardiac function must be acceptable for surgery according to institutional standards; 5. Acceptable hepatic, renal function.

Exclusion criteria

Exclusion criteria: 1. Other history of malignancy; 2. Stage investigations indicating unresectable advanced disease (T4 or M1a,M1b); 3. Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment; 4. Chemo and/or radiotherapy before surgery; 5. Patients medically unfit for surgical resection.

Design outcomes

Primary

Measure	Time frame
three-year disease-free survival;	—

Countries

China

Contacts

Public ContactLI BIN

Fudan University Shanghai Cancer Center

LB0256327@HOTMAIL.COM+86 18017317295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026